Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 15:12:1026251.
doi: 10.3389/fonc.2022.1026251. eCollection 2022.

Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience

Rossella Iula  1 , Danilo De Novellis  2   3 , Fabio Trastulli  4 , Roberta Della Pepa  1 , Raffaele Fontana  2 , Angela Carobene  2 , Maria Di Perna  5 , Alessandro D'Ambrosio  1 , Martina Romano  1 , Aldo Leone  1 , Laura De Fazio  1 , Alfonso Fiumarella  1 , Giuseppe Gaeta  1 , Violetta Marafioti  1 , Serafina Barbato  1 , Salvatore Palmieri  4 , Stefano Rocco  4 , Bianca Serio  2 , Catello Califano  5 , Fabrizio Pane  1 , Felicetto Ferrara  4 , Valentina Giudice  2   3 , Carmine Selleri  2   3 , Lucio Catalano  1
Affiliations

Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience

Rossella Iula et al. Front Oncol. .

Abstract

Belantamab-mafodotin is an innovative and selective treatment for multi-refractory/relapsed multiple myeloma (MM) patients; however, available real-life experiences on efficacy and safety are limited. In this real-world multicentric retrospective study, we enrolled 28 MM patients treated in four Hematology units of Campania region, Italy, who received a median of six treatment lines prior to belantamab-mafodotin. The overall response rate (ORR) was 40% (complete remission, CR, 11%; very good partial remission, VGPR, 11%; and partial remission, PR, 18%), with a median progression-free survival (PFS) and overall survival (OS) of 3 and 8 months, respectively. One of the most frequent drug-related adverse events was keratopathy observed in nine (32%) patients, leading to therapy discontinuation in only three (11%) of them. Moreover, 22 out of 28 total patients who were treated with at least two administrations achieved an ORR of 50% (CR, 14%; VGPR, 14%; and PR, 22%) with a median PFS and OS of 5 and 11 months, respectively. In conclusion, our multicentric study confirmed efficacy and safety of belantamab-mafodotin in triple-refractory MM patients even in the real-life setting.

Keywords: anti-BCMA; multi-refractory; multiple myeloma; real life; refractory.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Clinical outcomes of patients receiving belantamab-mafodotin. (A) Progression-free survival and (B) overall survival of multi-refractory/relapsed multiple myeloma patients of total cohort (N = 28) who received belantamab-mafodotin, and (C) progression-free survival and (D) overall survival of multirefractory/relapsed multiple myeloma patients of the evaluable cohort (N = 22) who received at least two belantamab-mafodotin administrations are shown. The number of censored subjects at risk is also reported.
Figure 2
Figure 2
Clinical outcomes based on overall response. Progression-free survival of multi-refractory/relapsed multiple myeloma patients who achieved at least a very good partial response (VgPR) was compared to that of subjects who achieved a partial remission (PR). The number of censored subjects at risk is also reported. A P < 0.05 was considered statistically significant.
See this image and copyright information in PMC

References

    1. Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. . Epidemiology, staging, and management of multiple myeloma. Med Sci (Basel) (2021) 9(1):3. doi: 10.3390/medsci9010003 - DOI - PMC - PubMed
    1. Gulla A, Anderson KC. Multiple myeloma: The (r)evolution of current therapy and a glance into future. Haematologica (2020) 105(10):2358–67. doi: 10.3324/haematol.2020.247015 - DOI - PMC - PubMed
    1. Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk (2020) 20(1):1–7. doi: 10.1016/j.clml.2019.09.621 - DOI - PubMed
    1. Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. . Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia (2019) 33(9):2266–75. doi: 10.1038/s41375-019-0435-7 - DOI - PMC - PubMed
    1. Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J (2020) 10(9):94. doi: 10.1038/s41408-020-00359-2 - DOI - PMC - PubMed